Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Allopurinol

FDA-approved product (tablet, oral), marketed as Allopurinol, Lopurin, Zyloprim and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Allopurinol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Gout
  • Leukemia
  • Lymphoma
  • Response Evaluation Criteria in Solid Tumors

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Preparations inhibiting uric acid production
FDA pharmacologic class
Xanthine Oxidase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Allopurinol, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA19.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis2.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 1 lab record
Open Allopurinol in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Allopurinol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug-Drug Interaction Study of ABP-671 in Gout Patients

    NCT07367971 · start 2026-01-23

    Registered record
    Registry ID
    NCT07367971
    Conditions
    Gout Chronic; Gout; DDI (Drug-Drug Interaction)
    Interventions
    ABP-671 plus allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-01-23
    Completion
    2026-08-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout Chronic; Gout; DDI (Drug-Drug Interaction)
    InterventionABP-671 plus allopurinol
    PhasePhase 1
    Registry statusRecruiting

  • A Study of Dotinurad Versus Allopurinol in Participants With Gout

    NCT07089875 · start 2025-08-01

    Registered record
    Registry ID
    NCT07089875
    Conditions
    Gout
    Interventions
    Allopurinol; Dotinurad
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2027-11-29
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionAllopurinol; Dotinurad
    PhasePhase 3
    Registry statusRecruiting

  • Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

    NCT05888233 · start 2024-09-30

    Registered record
    Registry ID
    NCT05888233
    Conditions
    Heart Failure Preserved Ejection Fraction; Resistant Hypertension
    Interventions
    Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-09-30
    Completion
    2026-08-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure Preserved Ejection Fraction; Resistant Hypertension
    InterventionAllopurinol
    PhasePhase 2
    Registry statusCompleted

  • Allopurinol and Pathogenesis of Cirrhosis

    NCT07033533 · start 2023-06-01

    Registered record
    Registry ID
    NCT07033533
    Conditions
    Cirrhoses, Liver
    Interventions
    Allopurinol Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2023-06-01
    Completion
    2024-03-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhoses, Liver
    InterventionAllopurinol Tablet; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Allo HSCT Using RIC and PTCy for Hematological Diseases

    NCT05805605 · start 2023-05-01

    Registered record
    Registry ID
    NCT05805605
    Conditions
    Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Biphenotypic Acute Leukemia; Undifferentiated Leukemia; Prolymphocytic Leukemia; Chronic Myelogenous Leukemia; Plasma Cell Leukemia; Myelodysplastic Syndromes; Leukemia, Myeloid; Myelodysplastic Syndrome With Excess Blasts-1; Burkitt Lymphoma; Relapsed T-Cell Lymphoma; Relapsed Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma; Follicular Lymphoma; Myeloproliferative Neoplasm; Myelofibrosis
    Interventions
    Peripheral Blood Stem Cell Transplant; Allopurinol 300 MG; Fludarabine; Cyclophosphamide; Bone Marrow Cell Transplant; Total Body Irradiation; Sirolimus Pill; Mycophenolate Mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-05-01
    Completion
    2028-10-22
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Biphenotypic Acute Leukemia; Undifferentiated Leukemia +14 more
    InterventionPeripheral Blood Stem Cell Transplant; Allopurinol 300 MG; Fludarabine; Cyclophosphamide +4 more
    PhasePhase 2
    Registry statusRecruiting

  • Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

    NCT05586971 · start 2023-03-30

    Registered record
    Registry ID
    NCT05586971
    Conditions
    Gout; Hyperuricemia; Gout Flare; Tophi
    Interventions
    Tigulixostat; Allopurinol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-03-30
    Completion
    2025-05-06
    Enrolment
    2,202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout; Hyperuricemia; Gout Flare; Tophi
    InterventionTigulixostat; Allopurinol; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

    NCT05536349 · start 2022-12-20

    Registered record
    Registry ID
    NCT05536349
    Conditions
    Leukemia
    Interventions
    Pirtobrutinib; Obinutuzumab; Venetoclax; Valacyclovir; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-12-20
    Completion
    2028-04-25
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionPirtobrutinib; Obinutuzumab; Venetoclax; Valacyclovir +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Allopurinol and Quality of Life in Liver Cirrhosis

    NCT05828836 · start 2022-06-15

    Registered record
    Registry ID
    NCT05828836
    Conditions
    Cirrhosis, Liver
    Interventions
    Allopurinol Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2022-06-15
    Completion
    2023-03-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver
    InterventionAllopurinol Tablet; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

    NCT04746989 · start 2021-02-01

    Registered record
    Registry ID
    NCT04746989
    Conditions
    Gout
    Interventions
    Probenecid; Allopurinol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-02-01
    Completion
    2023-12-31
    Enrolment
    294,878

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionProbenecid; Allopurinol
    PhaseNot recorded
    Registry statusCompleted

  • The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients：A Prospective Cohort Study

    NCT04213534 · start 2020-10-10

    Registered record
    Registry ID
    NCT04213534
    Conditions
    Gout
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-10-10
    Completion
    2023-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Allopurinol Effect on MDA,NO,KIM-1 Urine Levels, RI and Renal Elastography in Kidney Stone Patients Post ESWL

    NCT05414669 · start 2020-08-06

    Registered record
    Registry ID
    NCT05414669
    Conditions
    Kidney Calculi
    Interventions
    Allopurinol Tablet 300 mg; Control Group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-08-06
    Completion
    2021-04-20
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Calculi
    InterventionAllopurinol Tablet 300 mg; Control Group
    PhasePhase 4
    Registry statusCompleted

  • Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass

    NCT04217421 · start 2020-02-14

    Registered record
    Registry ID
    NCT04217421
    Conditions
    Congenital Heart Disease in Children; Neuroprotection
    Interventions
    Allopurinol; Mannitol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2020-02-14
    Completion
    2028-12-31
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Heart Disease in Children; Neuroprotection
    InterventionAllopurinol; Mannitol
    PhasePhase 3
    Registry statusRecruiting

  • Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

    NCT03865407 · start 2019-03-10

    Registered record
    Registry ID
    NCT03865407
    Conditions
    Hyperuricemia; Chronic Kidney Diseases
    Interventions
    Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-03-10
    Completion
    2020-10-07
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperuricemia; Chronic Kidney Diseases
    InterventionAllopurinol
    PhasePhase 2
    Registry statusTerminated

  • Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid

    NCT03648996 · start 2018-11-01

    Registered record
    Registry ID
    NCT03648996
    Conditions
    Diabetes Mellitus, Type 2; Hyperuricemia
    Interventions
    Low-fructose diet, isocaloric; Allopurinol; Placebo; Low-fructose, hypocaloric
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-11-01
    Completion
    2022-03-10
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Hyperuricemia
    InterventionLow-fructose diet, isocaloric; Allopurinol; Placebo; Low-fructose, hypocaloric
    PhasePhase 2
    Registry statusCompleted

  • The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction

    NCT03680404 · start 2018-10-01

    Registered record
    Registry ID
    NCT03680404
    Conditions
    Cardiovascular Diseases; Cardiovascular Risk Factor; Vasoconstriction
    Interventions
    Control (Phenylephrine); Phenylephrine + Apocynin; Phenylephrine + Allopurinol; Phenylephrine + Tempol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-10-01
    Completion
    2020-02-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Cardiovascular Risk Factor; Vasoconstriction
    InterventionControl (Phenylephrine); Phenylephrine + Apocynin; Phenylephrine + Allopurinol; Phenylephrine + Tempol
    PhasePhase 1
    Registry statusCompleted